


25 MAY 2001

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER
FORM PTO-1390 (REV 12-29-99)		MWH-0029US
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		
INTERNATIONAL APPLICATION NO. PCT/US99/27963	INTERNATIONAL FILING DATE 24 November 1999 (24.11.99)	PRIORITY DATE CLAIMED 25 November 1998 (25.11.98)
TITLE OF INVENTION Polymorphisms in the 5' Leader Cistron of the Beta2-Adrenergic Receptor		
APPLICANT(S) FOR DO/EO/US LIGGETT, Stephen B.		
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ul style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ul style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ul style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 		
<p>Items 11. to 16. below concern document(s) or information included:</p> <ul style="list-style-type: none"> 11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input checked="" type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input checked="" type="checkbox"/> A change of power of attorney and/or address letter. 16. <input checked="" type="checkbox"/> Other items or information: A revocation of power of attorney 		

U.S. APPLICATION NO. (if known, see 37 CFR 1.10) 097856803		INTERNATIONAL APPLICATION NO. PCT/US99/27963	ATTORNEY'S DOCKET NUMBER MWH-0029US
17. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):			
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00			
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00			
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$690.00			
International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00			
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00			
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 670.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$ 0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	24 - 20 =	4	X \$18.00 \$ 72.00
Independent claims	8 - 3 =	5	X \$78.00 \$ 400.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$260.00	\$ 0.00
TOTAL OF ABOVE CALCULATIONS =		\$ 1142.00	
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).		\$ 0.00	
SUBTOTAL =		\$ 1142.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		\$ 0.00	
TOTAL NATIONAL FEE =		\$ 1142.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property		+ \$ 0.00	
TOTAL FEES ENCLOSED =		\$ 1142.00	
		Amount to be refunded:	\$
		charged:	\$
<p>a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.</p> <p>b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>50-1293</u> in the amount of \$ <u>1142.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>50-1293</u>. A duplicate copy of this sheet is enclosed.</p>			
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>			
<p>SEND ALL CORRESPONDENCE TO:</p> <p>Gisela M. Field Genaissance Pharmaceuticals, Inc 5 Science Park New Haven, CT 06511</p>			
 <p>SIGNATURE: Gisela M. Field NAME 47,562 REGISTRATION NUMBER</p>			

09/856803

531 RE 1201 111 25 MAY 2001

Practitioner's Docket No. MWH-0029US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ligget, Stephen B.

Application No.: To be assigned
Filed: May 25, 2001

Group No.: To be assigned
Examiner: To be assigned

For: POLYMORPHISMS IN THE 5' LEADER CISTRON OF THE BETA2-ADRENERGIC
RECEPTOR

Assistant Commissioner for Patents
Washington, D.C. 20231

FIRST PRELIMINARY AMENDMENT TO CLAIMS
(37 C.F.R. 1.121 and M.P.E.P. 714.09)

This application is the National Phase filing of PCT/US99/27963. This paper is filed to cancel claims. Prior to calculating the filing fee, it is respectfully requested that the claims be amended as indicated below.


IN THE CLAIMS

Please cancel claims 22, 24, and 25 without prejudice or disclaimer.

REMARKS

This amendment cancels claims in order to facilitate prosecution of the application. Should any questions arise, or if Applicant or Applicant's Attorney can facilitate examination of this Application, please contact the undersigned Attorney at the phone number below.

Respectfully submitted,



Gisela M. Field
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511

Reg. No. 47,562
Tel. No. 203-786-3473

Practitioner's Docket No. MWH-0029US

PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Liggett, Stephen B.

Application No.: To be assigned
Filed: May 25, 2001Group No.: To be assigned
Examiner: To be assignedFor: POLYMORPHISMS IN THE 5' LEADER CISTRON OF THE BETA2-ADRENERGIC
RECEPTORAssistant Commissioner for Patents
Washington, D.C. 20231**SECOND PRELIMINARY AMENDMENT TO CLAIMS**
(37 C.F.R. 1.121 and M.P.E.P. 714.09)

This application is the National Phase filing of PCT/US99/27963. This paper is filed to amend claims in response to the International Preliminary Examination Report (IPER) mailed on March 6, 2001 and to add new dependent claims to the current application. The accompanying first preliminary amendment cancels claims prior to the calculation of the filing fee. The additional claims presented herein are not taken into account when calculating the filing fee. Please charge any additional claims fees to our deposit account 50-1293 or credit any excess thereto.

IN THE CLAIMS

Please amend the following claims:

19. (amended) A method for determining the frequency of a B₂AR genotype or a B₂AR haplotype in a population, comprising
 - (a) determining the B₂AR genotype or the B₂AR haplotype pair for [the B₂AR 5' gene that is present in] each member of the population and
 - (b) calculating the frequency any particular B₂AR genotype or B₂AR haplotype is found in the population.
26. (amended) A method for predicting a patient's bronchodilating response to an agonist of B₂AR, which comprises determining the patient's genotype for the B₂AR 5'LC polymorphic site, wherein a patient who is homozygous T at this site is unlikely to exhibit a bronchodilating response to the agonist and a patient who contains a C at this site is likely to exhibit a bronchodilating response against the agonist.

Please add the following claims:

28. The method of claim 18, wherein if the genotype of the 5'LC PS is cytosine then the genotype of +46PS is guanine, and if the genotype of 5'LC PS is thymine then the genotype of +46PS is adenine.
29. The method of claim 18, wherein the genotype of the 5'LC PS is cytosine then the genotype of +79PS is guanine, and if the genotype of 5'LC PS is thymine then the genotype of +79PS is cytosine.

REMARKS

Upon entry of the first and second preliminary amendments, claims 1-21, 23, and 26-29 will be pending. Claim 19 has been amended to overcome the inventive step objection in the IPER, which stated that claims 19 and 20 are obvious over Liggett, 1997, *Am. J. Respir. Crit. Care Med.* 156:S156-S162 in view of Turki et al., 1996, *Proc. Natl. Acad. Sci. USA* 93:10483-10488. The IPER asserted that, since claim 19 does not limit the definition of *B₂AR* 5' gene, the claim could encompass the determination of the genotype in the coding region of the gene, as disclosed in the cited Liggett reference. As amended, claim 19 specifies that the genotype to be determined is a *B₂AR genotype*, which is defined in the specification at page 12, lines 25-31 to require that the genotype include at least the polymorphic site in the 5'-leader cistron. This polymorphic site is not disclosed or suggested in either of the cited references. In addition, the IPER also stated that claim 19 was lacking clarity since it was not clear what was meant by a *B₂AR* 5' gene. As amended, claim 19 removes the phrase *B₂AR* 5' gene, and for reasons stated above, indicates that the region to be genotyped and haplotyped must contain at least the polymorphic site in the 5'-leader cistron. Thus, the Applicant respectfully submits that amended claim 19 overcomes the lack of inventive step objection as well as the lack of clarity objection.

Amended claim 26 and new claims 28 and 29, which depend from original claim 18, respectively, are directed to subject matter found in the originally filed specification. Support for amended claim 26 is found at page 25, lines 15-18. Support for claims 28 and 29 is found at page 15, lines 6-9. It is respectfully submitted that the new claims do not introduce new matter and their entry is respectfully requested. Should any questions arise, or if Applicant or Applicant's Attorney can facilitate examination of this Application, please contact the undersigned Attorney at the phone number below.

Respectfully Submitted,

Reg. No. 47,562
Tel. No. 203-786-3473

Gisela M. Zield

Gisela M. Field
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511

WO 00/31307

1

POLYMORPHISMS IN THE 5' LEADER CISTRON OF THE
 β_2 -ADRENERGIC RECEPTOR

This application is based on U.S. Provisional Application Serial No. 60/109,886, filed November 25, 1998.

5

Field of the Invention

This invention relates to the fields of pharmacogenomics, diagnostics and gene therapy. More specifically, the present invention relates to methods of screening drugs, which modulate the activity of the β_2 -adrenergic receptor as well as methods of diagnosing and/or treating diseases involving β_2 AR or its isoforms.

Background of the Invention

Studies over the last several years of mutations/polymorphisms in G-protein coupled receptor genes in the human population have revealed several classes of genetic variations. One class is composed of polymorphisms that alter receptor function or expression and are the direct cause of a disease. These diseases are typically rare and the polymorphism is not found in healthy (non-affected) individuals. Examples of this class are polymorphisms of the leutinizing hormone receptor that cause constitutive activation and results in familial male precocious puberty (Themmen, A.P.N. et al., *J Endocrinol* 153:179-183, 1997), the calcium sensing receptor which causes constitutive activation and results in familial hypoparathyroidism (Chattopadhyay, N. et al., *Endocr Rev* 17:289-307, 1996), and the V2 vasopressin receptor that causes depressed receptor function and results in nephrogenic diabetes insipidus (Rosenthal, W. A. et al., *J.Biol.Chem.* 268:13030-13033, 1993).

A second class of genetic variations of G-protein coupled receptors comprises those that alter receptor function or expression but do not appear to be the direct or sole cause of a disease. Here, the variation can be common in apparently healthy individuals. Studies to date indicate that these polymorphisms may act as disease modifiers (Liggett, S.B. 1996. The genetics of β_2 -adrenergic receptor polymorphisms: relevance to receptor function and asthmatic phenotypes. In *The Genetics of Asthma*. S.B. Liggett and D.A. Meyers, editors. Marcel Dekker, New York. 455-478) with the physiologic consequences becoming apparent when receptor function is critical for

compensation in the diseased state or for the response to therapy. As such, they may be responsible for certain clinical subsets of a given disease (such as different phenotypes of asthma or hypertension) or represent the basis of differential responsiveness to therapeutic agents.

5 β_2 -adrenergic receptors (β_2 AR) are G-protein coupled receptors that are activated by endogenous catecholamines. These receptors are widely distributed, and play important roles in regulating cardiac, vascular, pulmonary, and metabolic functions. Studies of such physiologic functions of β_2 AR in humans have revealed several observations. First, there appears to be substantial interindividual variation in 10 responsiveness, and secondly receptor function appears to be dynamically regulated as indicated by intraindividual variation. Recently, significant genetic variability in the structure of the β_2 AR in the human population due to polymorphisms in the β_2 AR gene has been delineated (1, 2). These polymorphisms are located 46, 79, 100 and 491 bases downstream of the ATG start codon, and result in variation that occurs in 15 the amino-terminus of the receptor at amino acids 16 (Arg or Gly), 27 (Gln or Glu) and 34 (Val or Met) and in the fourth transmembrane spanning domain at amino acid 164 (Thr or Ile). In recombinant cell studies (3, 4), and in primary cultures of cells endogenously expressing these variants (5), clear phenotypic differences have been shown between the polymorphic receptors. The Gly16 receptor was found to undergo 20 enhanced agonist-promoted downregulation of receptor number as compared to the Arg16 receptor (3). In contrast, the Glu27 receptor was found to undergo very little agonist-promoted downregulation compared to the Gln27 receptor (3). These variants are common in the population (1). The Ile164 receptor, which occurs in the heterozygous state in ~5% of the population, displays depressed coupling to the 25 stimulatory G protein, G_s (4).

Subsequent studies have assessed the role of the aforementioned polymorphic β_2 AR in diseases such as asthma [reviewed in (6)], based on the role of β_2 AR in modulating bronchial smooth muscle tone. In these studies, no differences in the frequencies of any of these polymorphisms between non-asthmatics and asthmatics 30 have been reported. However, polymorphisms at positions 16 and 27 were found to act as significant disease modifiers (7-10). In the majority of the above cited studies, the presumption has been that the clinical phenotypes of those with the Gly16

polymorphism were due to enhanced downregulation of this receptor (as compared to those with the Arg16 receptor) by endogenous catecholamines. Thus responsiveness to β -agonists in individuals with this polymorphism has been considered depressed due to this tonic downregulation. A similar scenario is considered in individuals with 5 the Glu27 variant, who exhibit greater responsiveness to β -agonists than those individuals with the Gln27 receptor, presumably due to its minimal downregulation by catecholamines. An amplification of these differences may occur during chronic agonist administration, as has recently been shown in asthma (11).

The β_2 AR is encoded by an intronless gene on chromosome 5q31 (12).

10 Receptor transcripts have a 5' leader region harboring an open reading frame (ORF) that encodes a 19 amino acid peptide (13). Recent *in vivo* and *in vitro* studies have shown that this peptide impedes translation of β_2 AR mRNA, and thus regulates cellular expression of the receptor (14). Given the importance of this 5' leader cistron in controlling β_2 AR expression, this region in the human population was examined for 15 genetic variability.

Summary of the Invention

The present invention is based on the discovery of a common polymorphism that is located in the 5' leader cistron (5'LC) of the β_2 AR gene. In particular, a 20 polymorphism of cytosine or thymine located 47 bases upstream of the β_2 AR coding block results in either Arg or Cys being encoded at the terminal amino acid (position 19) of the 5'LC peptide (Arg19Cys) (see Figs. 1-3; SEQ ID NOS:1-3, respectively). The inventor herein has also discovered that a substitution of Cys for Arg in the 5'LC peptide results in increased expression of β_2 AR in both recombinant and airway 25 smooth muscle cells, which endogenously express β_2 AR. Thus, it is believed this β_2 AR 5' LC polymorphic site represents, at least in part, the genetic basis of variable physiologic sympathetic responses, variation in disease phenotypes, and differences in the therapeutic efficacy of β -agonists and β -antagonists.

Thus, in one aspect the present invention provides methods and compositions 30 for genotyping and haplotyping the β_2 AR gene of an individual. In one embodiment, a genotyping method comprises isolating from the individual a nucleic acid mixture comprising the two copies of the β_2 AR gene present in the individual and determining

the identity of the nucleotide pair at the 5'LC polymorphic site in the two copies to assign a β_2 AR genotype to the individual. The haplotyping method comprises isolating from the individual a nucleic acid molecule containing only one of the two copies of the β_2 AR gene, or a fragment thereof, that is present in the individual and determining in that copy the identity of the nucleotide at the 5'LC PS and at one or more additional β_2 AR polymorphic sites. Compositions useful in performing the genotyping and haplotyping methods include oligonucleotide probes and primers designed to specifically hybridize to a target region containing the 5'LC polymorphic site. These genotyping methods and compositions are useful for studying the effect of the 5'LC polymorphisms in the etiology of various diseases and efficacy of drugs targeting the β_2 AR.

In another embodiment, the invention provides a method for detecting which variant(s) of the 5'LC peptide is expressed in an individual. The method comprises contacting a biological sample from the individual with a first antibody that specifically recognizes and binds to only one of the β_2 AR 5'LC peptide variants and detecting a complex formed with the first antibody. In a preferred embodiment, the method further comprises contacting the biological sample with a second antibody that specifically recognizes and binds to the other β_2 AR 5'LC peptide variant and detecting a complex formed with the second antibody. This method is useful for investigating the effects of the 5'LC peptide variants on β_2 AR expression. In addition, the preferred embodiment is useful to determine the genotype. If both antibodies react with the sample, the individual is heterozygous C/T at the 5'LC polymorphic site.

Another aspect of the invention is based on the discovery that β_2 AR alleles carrying the 5'LC C polymorphism are most likely to also have the polymorphisms which encode Gln and Arg at amino acids 16 and 27, respectively. Thus, the genotype for the 5'LC polymorphic site may be used to predict the identity of the genotype for one or both of these β_2 AR coding block polymorphisms.

In yet another embodiment, the invention provides a method for identifying an association between a β_2 AR 5'LC genotype and a trait. The method comprises comparing the frequency of the β_2 AR 5'LC genotype in a population exhibiting the trait with the frequency of the genotype in a reference population, wherein a higher

frequency of the genotype in the trait population than in the reference population indicates the trait is associated with the genotype. Such methods have applicability in developing diagnostic tests and therapeutic treatments for a variety of diseases, including arrhythmia, heart failure, hypertension, vascular disease, migraine, asthma, 5 chronic obstructive pulmonary disease (COPD), anaphylaxis, obesity, diabetes and premature labor.

The present invention also provides a method for predicting an individual's genetic predisposition to a disease modified by the β_2 AR. The method comprises determining the individual's genotype for the 5'LC polymorphic site. If the 10 individual is homozygous T, increased β_2 AR expression is likely and the individual has an increased risk for diseases affected by too much β_2 AR expression. If the individual is homozygous C, decreased β_2 AR expression is likely and the individual has an increased risk for diseases affected by too little β_2 AR expression. In a preferred embodiment, the disease modified by the β_2 AR is selected from the group 15 consisting of arrhythmia, heart failure, hypertension, vascular disease, migraine, asthma, chronic obstructive pulmonary disease (COPD), anaphylaxis, obesity, diabetes and premature labor.

The present invention further provides methods for predicting a patient's response to β -agonist therapy for bronchospasm, which typically occurs in asthma, 20 COPD and anaphylaxis. In one embodiment, the method comprises determining the genotype of the 5'LC polymorphic site in the patient's β_2 AR gene. If the patient is homozygous for the T polymorphism, failure to respond to a β -agonist is likely, while a patient is likely to respond if he or she is homozygous for the C polymorphism or is 25 heterozygous T/C at this site. Thus, knowledge of a patient's β_2 AR 5'LC genotype provides a physician with information useful for making determinations as to which drug to administer, drug dosages, and duration of treatment.

Brief Description of the Figures

Figure 1 illustrates a partial DNA sequence for one allele of the human β_2 AR gene (SEQ ID NO:1), with the boxed region indicating the ORF for the 5' leader 30 cistron, the underline indicating the start codon for the ORF encoding the β_2 AR

protein (also referred to herein as the β_2 AR coding block), and the location of the novel polymorphic site described herein indicated in bold.

Figure 2 illustrates the DNA sequence of the β_2 AR 5' leader cistron containing the thymidine polymorphism (SEQ ID NO:2) at nucleotide 55 instead of the cytosine polymorphism shown in Figure 1.

Figure 3 illustrates the amino acid sequence of the Cys variant of the β_2 AR 5' leader cistron peptide (SEQ ID NO:3).

Figure 4 illustrates identification of the polymorphic site in the 5' leader cistron of the human β_2 AR gene, with Fig. 4A showing representative antisense sequencing results from two homozygous individuals and Fig. 4B showing representative restriction digests of a 163 bp PCR product digested with MspAI.

Figure 5A shows a graph of the level of β_2 AR expression in COS-7 cells transfected with one of the 5'LC-Arg 19 or the 5'LC-Cys19 constructs described in the Examples with β_2 AR levels determined by radioligand binding with [125 I]CYP performed in triplicate and presented as fmol receptor/mg membrane protein.

Figure 5B shows a graph of β_2 AR expression in cells co-transfected with one of the above 5'LC constructs and a construct encoding firefly luciferase, with β_2 AR expression presented as fmol receptor/light unit receptor.

Figure 6 illustrates the results of ribonuclease protection assays, which identify levels of β_2 AR mRNA and actin mRNA in COS-7 cells transfected with one of the above 5'LC constructs.

Figure 7 shows a graph of β_2 AR expression in primary cultures of human airway smooth muscle cells (HASM) homozygous for the 5'LC C allele (Arg19) or homozygous for the 5'LC T allele (Cys19).

Figure 8 shows a graph relating genotype for the 5'LC polymorphic site and the percent of patients who responded to the β -agonist albuterol.

Description of the Preferred Embodiments

In accordance with the present invention, the inventor herein has discovered a common polymorphism of C or T in the 5' leader cistron of the β_2 AR gene. The C allele of this polymorphism encodes Arg at position 19 of the 5'LC peptide (MRLPGVRSRPAEPRRGSGAR) (SEQ ID NO:4) while the T allele encodes Cys at

this position (MRLPGVRSRPAEPRRG SAC) (SEQ ID NO:3). As demonstrated in the Examples below, β_2 AR expression is significantly increased in cells homozygous for the T allele as compared to cells homozygous for the C allele. The studies described herein also show that the polymorphism probably does not affect transcription of the β_2 AR gene, which is consistent with an earlier study that concluded that the 5'LC peptide inhibits translation (14). In addition, the examples below demonstrate that the 5'LC C polymorphism is in linkage disequilibrium with the β_2 AR coding block polymorphisms that encode Arg16 and Gln27. Because the β_2 AR is expressed in virtually every tissue of the body, it is believed an individual's genotype for the 5'LC polymorphism of the present invention has the potential to influence, or be a marker of, his or her genetic predisposition for various diseases, including asthma, hypertension, congestive heart failure, ischemic heart disease, arrhythmia, obesity, diabetes, vascular disease, and premature labor.

In the context of this disclosure, the following terms shall be defined as follows unless otherwise indicated:

Allele - A particular form of a genetic locus, distinguished from other forms by its particular nucleotide or amino acid sequence.

Gene - A segment of DNA that contains all the information for the regulated biosynthesis of an RNA product, including promoters, exons, introns, and other untranslated regions that control expression.

Genotype - An unphased 5' to 3' sequence of nucleotide pair(s) found at one or more polymorphic sites in a locus on a pair of homologous chromosomes in an individual.

Genotyping - A process for determining a genotype of an individual.

Haplotype - A phased 5' to 3' sequence of nucleotides found at two or more polymorphic sites in a locus on a single chromosome from a single individual.

Haplotyping - A process for determining a haplotype of an individual.

Haplotype pair - The two haplotypes found for a locus in a single individual.

Isoform - A particular form of a gene, mRNA, cDNA or the protein encoded thereby, distinguished from other forms by its particular sequence and/or structure.

Isolated - As applied to a biological molecule such as RNA, DNA, oligonucleotide, or protein, isolated means the molecule is for practical purposes free

of other biological molecules such as non-desired nucleic acids, proteins, lipids, carbohydrates, or other material such as cellular debris and growth media. Generally, the term "isolated" is not intended to refer to a complete absence of such material or to absence of water, buffers, or salts, unless they are present in amounts that substantially interfere with the methods of the present invention.

5 **Locus** - A location on a chromosome or DNA molecule corresponding to a gene or a physical or phenotypic feature.

10 **Naturally-occurring** – A term used to designate that the object it is applied to, e.g., naturally-occurring polynucleotide or polypeptide, can be isolated from a source in nature and which has not been intentionally modified by man.

15 **Nucleotide pair** – The nucleotides found at a polymorphic site on corresponding strands of the two copies of a chromosome in an individual.

20 **Phasing** – The description of the identity of the nucleotides at two or more polymorphic sites in the same linear genetic molecule.

15 **Polymorphic site (PS)** – A position within a locus at which at least two alternative sequences are found in a population.

20 **Polymorphic variant** – A gene, mRNA, cDNA, polypeptide or peptide whose nucleotide or amino acid sequence varies from a reference sequence due to the presence of a polymorphism in the gene.

25 **Polymorphism** – The sequence variation observed in an individual at a polymorphic site. Polymorphisms include nucleotide substitutions, insertions, deletions and microsatellites and may, but need not, result in detectable differences in gene expression or protein function.

20 **Polynucleotide** – A nucleic acid molecule comprised of single-stranded RNA or DNA or comprised of complementary, double-stranded DNA.

25 **Reference Population** - A group of subjects or individuals who are predicted to be representative of the genetic variation found in the general population. In preferred embodiments, the reference population represents the genetic variation in the population at a certainty level of at least 85%, preferably at least 90%, more preferably at least 95% and even more preferably at least 99%.

30 **Single Nucleotide Polymorphism (SNP)** – Typically, the specific pair of nucleotides observed at a single polymorphic site. In rare cases, three or four nucleotides may be found.

Treatment - A stimulus administered internally or externally to an individual.

Population Group – A group of individuals sharing a common ethnogeographic origin.

Information on the identity of the β_2 AR 5'LC polymorphism(s) present in any particular individual as well as the frequency of the two alleles for this polymorphic site in any particular population of individuals is expected to be useful for a variety of basic research and clinical applications. Thus, the invention provides compositions and methods for detecting the β_2 AR 5'LC polymorphisms described herein.

The compositions comprise oligonucleotide probes and primers capable of hybridizing to a target region containing the 5'LC polymorphic site or defining this target region for amplification. As used herein, the term "oligonucleotide" refers to a polynucleotide molecule having less than about 100 nucleotides. A preferred oligonucleotide of the invention is 10 to 35 nucleotides long. More preferably, the oligonucleotide is between 15 and 30, and most preferably, between 20 and 25 nucleotides in length. The oligonucleotide may be comprised of any phosphorylation state of ribonucleotides, deoxyribonucleotides, and acyclic nucleotide derivatives, and other functionally equivalent derivatives. Alternatively, oligonucleotides may have a phosphate-free backbone, which may be comprised of linkages such as carboxymethyl, acetamide, carbamate, polyamide (peptide nucleic acid (PNA)) and the like (Varma, R. in *Molecular Biology and Biotechnology, A Comprehensive Desk Reference*, Ed. R. Meyers, VCH Publishers, Inc. (1995), pages 617-620).

Oligonucleotides of the invention may be prepared by chemical synthesis using any suitable methodology known in the art, or may be derived from a biological sample, for example, by restriction digestion. The oligonucleotides may be labeled, according to any technique known in the art, including the use of radiolabels, fluorescent labels, enzymatic labels, proteins, haptens, antibodies, sequence tags and the like.

Oligonucleotide probes and primers of the invention must be capable of specifically hybridizing to a target region of a β_2 AR polynucleotide, i.e., a β_2 AR gene, cDNA, or mRNA. As used herein, specific hybridization means the oligonucleotide reacts with the target region with sufficient specificity to allow the skilled artisan to discriminate between hybridization to the target region and hybridization to a non-target region. Preferably, the oligonucleotide specifically hybridizes to the target

region under conventional high stringency conditions. The skilled artisan can readily design and test oligonucleotide probes and primers suitable for detecting the β_2 AR 5'LC polymorphisms using the information provided herein in conjunction with the known sequence information for the β_2 AR gene and routine techniques.

5 In describing the β_2 AR 5'LC polymorphic site identified herein, reference is
made to the sense strand of the gene for convenience. However, as recognized by the
skilled artisan, nucleic acid molecules containing the β_2 AR gene may be
complementary double stranded molecules and thus reference to a particular site on
the sense strand refers as well to the corresponding site on the complementary
10 antisense strand. Thus, reference may be made to either strand and still comprise the
same polymorphic site and an oligonucleotide may be designed to specifically
hybridize to either strand. Thus, the invention also includes oligonucleotides which
are complementary to the sense strand of the β_2 AR 5' gene.

A nucleic acid molecule such as an oligonucleotide or polynucleotide is said to be a “perfect” or “complete” complement of another nucleic acid molecule if every nucleotide of one of the molecules is complementary to the nucleotide at the corresponding position of the other molecule. A nucleic acid molecule is “substantially complementary” to another molecule if it hybridizes to that molecule with sufficient stability to remain in a duplex form under conventional low-stringency conditions. Conventional hybridization conditions are described, for example, by Sambrook J. et al., in *Molecular Cloning, A Laboratory Manual, 2nd Edition*, Cold Spring Harbor Press, Cold Spring Harbor, NY (1989) and by Haymes, B.D. et al. in *Nucleic Acid Hybridization, A Practical Approach*, IRL Press, Washington, D.C. (1985). While perfectly complementary oligonucleotides are preferred for detecting polymorphisms, departures from complete complementarity are contemplated where such departures do not prevent the molecule from specifically hybridizing to the target region. For example, an oligonucleotide primer may have a non-complementary fragment at its 5' end, with the remainder of the primer being complementary to the target region. Alternatively, non-complementary nucleotides may be interspersed into the oligonucleotide probe or primer as long as the resulting probe or primer is still capable of specifically hybridizing to the target region.

Preferred oligonucleotides of the invention are allele-specific oligonucleotides. As used herein, the term allele-specific oligonucleotide (ASO) means an oligonucleotide that is able, under sufficiently stringent conditions, to specifically hybridize to one allele of the β_2 AR 5'LC or other β_2 AR locus, at a target region containing a polymorphic site while not hybridizing to the corresponding region in another allele(s). As understood by the skilled artisan, allele-specificity will depend upon a variety of readily optimized stringency conditions, including salt and formamide concentrations, as well as temperatures for both the hybridization and washing steps. Examples of hybridization and washing conditions typically used for ASO probes are found in Kogan et al., "Genetic Prediction of Hemophilia A" in *PCR Protocols, A Guide to Methods and Applications*, Academic Press, 1990 and Ruano et al., 87 *Proc. Natl. Acad. Sci. USA* 6296-6300, 1990. Typically, an allele-specific oligonucleotide will be perfectly complementary to one allele while containing a single mismatch for another allele.

Allele-specific oligonucleotide probes which usually provide good discrimination between different alleles are those in which a central position of the oligonucleotide probe aligns with the polymorphic site in the target region (e.g., approximately the 7th or 8th position in a 15 mer, the 8th or 9th position in a 16mer, the 10th or 11th position in a 20 mer). A preferred ASO probe for detecting β_2 AR 5'LC polymorphisms comprises a nucleotide sequence selected from the group consisting of: 5'- GTCCGCCCGCTGAGG -3' (SEQ ID NO:5) or its complement and 5'- GTCCGCCTGCTGAGG -3' (SEQ ID NO:6) or its complement.

An allele-specific oligonucleotide primer of the invention has a 3' terminal nucleotide, or preferably a 3' penultimate nucleotide, that is complementary to only one nucleotide of a particular SNP, thereby acting as a primer for polymerase-mediated extension only if the allele containing that nucleotide is present. Allele-specific oligonucleotide primers hybridizing to either the coding or noncoding strand are contemplated by the invention. A preferred ASO forward primer for detecting β_2 AR 5'LC polymorphisms comprises a nucleotide sequence selected from the group consisting of 5'- CCCCGCCGTGGGTCCGCCG -3' (SEQ ID NO:7) and 5'- CCCCGCCGTGGGTCCGCCTG -3' (SEQ ID NO:8). A preferred ASO reverse primer for detecting β_2 AR 5'LC polymorphisms comprises a nucleotide sequence

selected from the group consisting of 5'- GGCTGGGGCGCCTCAGCGG -3' (SEQ ID NO:9) and 5'- GGCTGGGGCGCCTCAGCAG -3' (SEQ ID NO:10).

In some embodiments, a composition contains two or more differently labeled allele-specific oligonucleotides for simultaneously probing the identity of nucleotides 5 at the β_2 AR 5'LC polymorphic site and one or more additional polymorphic sites in the β_2 AR gene or other locus. It is also contemplated that primer compositions may contain two or more sets of allele-specific primer pairs to allow simultaneous targeting and amplification of two or more regions containing a β_2 AR polymorphic site, one of which is the β_2 AR 5'LC polymorphic site.

10 Allele-specific oligonucleotides of the invention may also be immobilized on or synthesized on a solid surface such as a microchip, bead, or glass slide (see, e.g., WO 98/20020 and WO 98/20019). Such immobilized allele-specific oligonucleotides may be used in a variety of polymorphism detection assays, including but not limited to probe hybridization and polymerase extension assays. Immobilized ASO's of the 15 invention may comprise an ordered array of oligonucleotides designed to rapidly screen a DNA sample for polymorphisms in multiple genes at the same time.

In another embodiment, the invention provides a kit comprising at least two allele-specific oligonucleotides for detecting β_2 AR 5'LC polymorphisms packaged in separate containers. The kit may also contain other components such as hybridization 20 buffer (where the oligonucleotides are to be used as probes) packaged in another separate container. Alternatively, where the oligonucleotides are to be used to amplify a target region, the kit may also contain, a polymerase and a reaction buffer optimized for primer extension mediated by the polymerase, such as PCR.

These oligonucleotide compositions and kits are useful in methods for 25 genotyping and/or haplotyping the β_2 AR gene in an individual. As used herein the term " β_2 AR genotype" means the genotype contains at least the nucleotide pair present at the 5'LC PS and may optionally include the nucleotide pair(s) present at one or more additional polymorphic sites in the β_2 AR gene. Similarly, the term 30 " β_2 AR haplotype" means the haplotype contains the nucleotide present at the 5'LC PS as well as the nucleotide(s) present at one or more additional polymorphic sites in the β_2 AR gene. The additional polymorphic sites in these genotyping and haplotyping may be currently known polymorphic sites or sites that are subsequently discovered.

In preferred embodiments, the additional polymorphic sites are located 20 nucleotides upstream of the start codon and coding block polymorphic sites located 46, 79, 100 and 491 nucleotides downstream of the coding block ATG site. These sites are also referred to herein as -20 PS, +46 PS, +79 PS, +100 PS, and +491 PS.

5 One embodiment of the genotyping method comprises isolating from the individual a nucleic acid mixture comprising the two copies of the β_2 AR gene, or a fragment thereof, that are present in the individual and determining the identity of the nucleotide pair at the 5'LC polymorphic site (5'LC PS) in the two copies in order to assign a β_2 AR genotype to the individual. As will be readily understood by the
10 skilled artisan, the two "copies" of a gene in an individual may be the same allele or may be different alleles. Typically, the nucleic acid mixture is isolated from a biological sample taken from the individual, such as a blood sample or tissue sample. Suitable tissue samples include whole blood, semen saliva, tears, urine, fecal material, sweat, buccal, skin and hair. The nucleic acid mixture may be comprised of genomic
15 DNA, mRNA, or cDNA and, in the latter two cases, the biological sample must be obtained from an organ in which the β_2 AR gene is expressed. In a preferred embodiment, the β_2 AR genotype also comprises the nucleotide pair at one or more additional polymorphic sites in the β_2 AR gene. If a β_2 AR gene fragment is isolated, it must contain the 5'LC PS and any other β_2 AR sites to be genotyped.

20 One embodiment of the haplotyping method comprises isolating from the individual a nucleic acid molecule containing only one of the two copies of the β_2 AR gene, or a fragment thereof, that is present in the individual and determining in that copy the identity of the nucleotide at the 5'LC PS and at one or more additional β_2 AR polymorphic sites. In a preferred embodiment, the additional β_2 AR polymorphic
25 site(s) is selected from the group consisting of -20 PS, +46 PS, +79 PS, +100 PS and +491 PS. The nucleic acid may be isolated using any method that allows separation of the two copies of the β_2 AR gene present in an individual. Such methods include targeted *in vivo* cloning (TIVC) in yeast as described in WO 98/01573, U.S. Patent No. 5,866,404, and U.S. Patent No. 5,972,614. As will be readily appreciated by
30 those skilled in the art, any individual clone will provide haplotype information on only one of the two β_2 AR gene copies present in an individual. If haplotype information is desired for the individual's other copy, additional β_2 AR clones will

need to be examined. Typically, at least five clones will need to be examined to have more than a 90% probability of haplotyping both copies of the β_2 AR gene in an individual. Another method for separating the two copies of the β_2 AR gene, which is described in U.S. Patent No. 5,972,614, uses an allele specific oligonucleotide in combination with primer extension and exonuclease degradation to generate hemizygous DNA targets. Yet other methods are single molecule dilution (SMD) as described in Ruano et al., *Proc. Natl. Acad. Sci.* 87:6296-6300, 1990; and allele specific PCR (Ruano et al., 17 *Nucleic Acids Res.* 8392, 1989; Ruano et al., 19 *Nucleic Acids Res.* 6877-6882, 1991; Michalatos-Beloin et al., 24 *Nucleic Acids Res.* 10 4841-4843, 1996).

In another embodiment of the haplotyping method, a β_2 AR haplotype pair is determined for an individual by identifying the nucleotide at the 5'LC PS and one or more β_2 AR polymorphic sites. Preferably, the additional polymorphic site(s) is selected from the group consisting of -20 PS, +46 PS, +79 PS, +100 PS and +491 PS in both copies of the β_2 AR gene present in the individual. In a particularly preferred embodiment, the haplotyping method comprises identifying the nucleotide at each of the 5'LC PS, -20 PS, +46 PS, +79 PS, +100 PS and +491 PS in both copies of the β_2 AR gene present in the individual. When haplotyping both copies, the identifying step is preferably performed using first and second polynucleotides comprising each copy placed in separate containers. However, it is also envisioned that if the first and second polynucleotides are labeled with different tags, or are otherwise separately distinguishable or identifiable, it could be possible in some cases to perform the method in the same container. For example, if first and second polynucleotides are labeled with different first and second fluorescent dyes, respectively, and an allele-specific oligonucleotide labeled with yet a third different fluorescent dye is used to assay the polymorphic site(s), then detecting a combination of the first and third dyes would identify the polymorphism in the first polynucleotide while detecting a combination of the second and third dyes would identify the polymorphism in the second polynucleotide.

As described above and in the Examples below, the 5'LC thymine allele exhibits linkage disequilibrium with the coding block polymorphisms encoding the Arg16 and Gln27 β_2 AR variants and vice versa, the 5'LC cytosine allele is linked to

the coding block polymorphisms encoding the Gly16 and Glu27 β_2 AR variants. This relationship is the basis for another embodiment of the invention, which is a method for predicting an individual's genotype at one or both of +46 PS and +79 PS. The method comprises determining the individual's genotype at the 5'LC PS and

5 assigning a genotype for one or both of +46 PS and +79 PS that is consistent with the 5'LC genotype. If the 5'LC genotype is homozygous T, the genotype at +46 PS is probably homozygous A and the genotype at +79 PS is probably homozygous C, while conversely, if the 5'LC genotype is homozygous C, the genotype at +46 PS is probably homozygous G and the genotype at +79 PS is probably homozygous G.

10 It is also contemplated that the above genotyping and haplotyping methods of the invention may be performed in combination with identifying the genotype(s) and/or haplotype(s) for other genomic regions.

In the genotyping and haplotyping methods of the invention, the identity of a nucleotide (or nucleotide pair) at a polymorphic site may be determined by amplifying 15 a target region(s) containing the polymorphic site(s) directly from one or both copies of the β_2 AR gene present in the individual and the sequence of the amplified region(s) determined by conventional methods. It will be readily appreciated by the skilled artisan that only one nucleotide will be detected at a polymorphic site in individuals who are homozygous at that site, while two different nucleotides will be detected if 20 the individual is heterozygous for that site. The polymorphism may be identified directly, known as positive-type identification, or by inference, referred to as negative-type identification. For example, where a SNP is known to be guanine and cytosine in a reference population, a site may be positively determined to be either guanine or cytosine for an individual homozygous at that site, or both guanine and 25 cytosine, if the individual is heterozygous at that site. Alternatively, the site may be negatively determined to be not guanine (and thus cytosine/cytosine) or not cytosine (and thus guanine/guanine).

Since an MspA1I restriction site is lost when the T allele is present at the 5'LC PS, the identity of the nucleotide at the 5'LC PS may also be determined by digesting 30 an amplified target region containing this site with MspA1I and then analyzing the reaction products by standard size separation techniques such as agarose or polyacrylamide gel electrophoresis. The presence or absence of the enzyme restriction site as determined by this MspA1I restriction fragment length

polymorphism (RFLP) analyses is used to determine whether the individual being tested is homozygous for the C allele or T allele, respectively. The presence of both undigested and digested reaction products indicates the individual is heterozygous C/T at the 5'LC polymorphic site. In a preferred embodiment, the forward and 5 reverse primers used to amplify the target region comprise the following sequences 5'-GCTGAATGAGGCTTCCAGGC-3' (SEQ ID NO:13) and 5'-CGCATGGCTTCTATTGGGTG-3' (SEQ ID NO:14), respectively.

The target region(s) may be amplified using any oligonucleotide-directed amplification method, including but not limited to polymerase chain reaction (PCR) 10 (U.S. Patent No. 4,965,188), ligase chain reaction (LCR) (Barany et al., *Proc. Natl. Acad. Sci. USA* 88:189-193, 1991; WO90/01069), and oligonucleotide ligation assay (OLA) (Landegren et al., *Science* 241:1077-1080, 1988). Oligonucleotides useful as primers or probes in such methods should specifically hybridize to a region of the nucleic acid that contains or is adjacent to the polymorphic site. Typically, the 15 oligonucleotides are between 10 and 35 nucleotides in length and preferably, between 15 and 30 nucleotides in length. Most preferably, the oligonucleotides are 20 to 25 nucleotides long. The exact length of the oligonucleotide will depend on many factors that are routinely considered and practiced by the skilled artisan.

Other known nucleic acid amplification procedures may be used to amplify 20 the target region including transcription-based amplification systems (U.S. Patent No. 5,130,238; EP 329,822; U.S. Patent No. 5,169,766, WO89/06700) and isothermal methods (Walker et L., *Proc. Natl. Acad. Sci. USA* 89:392-396, 1992).

A polymorphism in the target region may also be assayed before or after amplification using one of several hybridization-based methods known in the art. 25 Typically, allele-specific oligonucleotides are utilized in performing such methods. The allele-specific oligonucleotides may be used as differently labeled probe pairs, with one member of the pair showing a perfect match to one variant of a target sequence and the other member showing a perfect match to a different variant. In some embodiments, more than one polymorphic site may be detected at once using a 30 set of allele-specific oligonucleotides or oligonucleotide pairs. Preferably, the members of the set have melting temperatures within 5°C, and more preferably within 2°C, of each other when hybridizing to each of the polymorphic sites being detected.

Hybridization of an allele-specific oligonucleotide to a target polynucleotide may be performed with both entities in solution, or such hybridization may be performed when either the oligonucleotide or the target polynucleotide is covalently or noncovalently affixed to a solid support. Attachment may be mediated, for example, by antibody-antigen interactions, poly-L-Lys, streptavidin or avidin-biotin, salt bridges, hydrophobic interactions, chemical linkages, UV cross-linking baking, etc. Allele-specific oligonucleotides may be synthesized directly on the solid support or attached to the solid support subsequent to synthesis. Solid-supports suitable for use in detection methods of the invention include substrates made of silicon, glass, plastic, paper and the like, which may be formed, for example, into wells (as in 96-well plates), slides, sheets, membranes, fibers, chips, dishes, and beads. The solid support may be treated, coated or derivatized to facilitate the immobilization of the allele-specific oligonucleotide or target nucleic acid.

The genotype or haplotype for one or more polymorphic sites in the β_2 AR gene of an individual may also be determined by hybridization of one or both copies of the gene, or a fragment thereof, to nucleic acid arrays and subarrays such as described in WO 95/11995. The arrays would contain a battery of allele-specific oligonucleotides representing each of the polymorphic sites to be included in the genotype or haplotype.

The identity of polymorphisms may also be determined using a mismatch detection technique, including but not limited to the RNase protection method using riboprobes (Winter et al., *Proc. Natl. Acad. Sci. USA* 82:7575, 1985; Meyers et al., *Science* 230:1242, 1985) and proteins which recognize nucleotide mismatches, such as the *E. coli* mutS protein (Modrich, P. *Ann. Rev. Genet.* 25:229-253 (1991)).

Alternatively, variant alleles can be identified by single strand conformation polymorphism (SSCP) analysis (Orita et al., *Genomics* 5:874-879, 1989; Humphries et al., in *Molecular Diagnosis of Genetic Diseases*, R. Elles, ed., pp 321-340, 1996) or denaturing gradient gel electrophoresis (DGGE) (Wartell et al., *Nucl. Acids Res.* 18:2699-2706, 1990; Sheffield et al., *Proc. Natl. Acad. Sci. USA* 86:232-236, 1989).

A polymerase-mediated primer extension method may also be used to identify the polymorphism(s). Several such methods have been described in the patent and scientific literature and include the "Genetic Bit Analysis" method (WO92/15712) and the ligase/polymerase mediated genetic bit analysis (U.S. Patent 5,679,524).

Related methods are disclosed in WO91/02087, WO90/09455, WO95/17676, and U.S. Patent No. 5,302,509. Another such method is allele-specific PCR (Ruano et al., *Nucl. Acids Res.* 17:8392, 1989; Ruano et al., *Nucl. Acids Res.* 19, 6877-6882, 1991; WO 93/22456; Turki et al., *J. Clin. Invest.* 95:1635-1641, 1995). In addition, multiple polymorphic sites may be investigated by simultaneously amplifying multiple regions of the nucleic acid using sets of allele-specific primers as described in Wallace et al. (WO89/10414).

Another aspect of the invention relates to detecting which variant(s) of the 5'LC peptide is expressed in an individual. In one embodiment, a biological sample from the individual is contacted with a first antibody that is specifically immunoreactive with only one of the 5'LC peptide variants and the formation of a complex with the first antibody is detected. In a preferred embodiment, the method also comprises contacting the biological sample with a second antibody that is specifically immunoreactive with the other 5'LC peptide variant and the formation of a complex with the second antibody is detected. Complex formation with both first and second antibodies indicate the individual is heterozygous at the β_2 AR 5'LC polymorphic site.

Suitable immunoassays for use in this detection method include radioimmunoassay, Western blot assay, immunofluorescent assay, enzyme linked immunoassay (ELISA), chemiluminescent assay, immunohistochemical assay, immunocytochemical assay, and the like (see, e.g., *Principles and Practice of Immunoassay*, 1991, Eds. Christopher P. Price and David J. Neoman, Stockton Press, New York, New York; *Current Protocols in Molecular Biology*, 1987, Eds. Ausubel et al., John Wiley and Sons, New York, New York). Standard techniques known in the art for ELISA are described in *Methods in Immunodiagnosis*, 2nd Ed., Eds. Rose and Bigazzi, John Wiley and Sons, New York 1980; and Campbell et al., 1984, *Methods in Immunology*, W.A. Benjamin, Inc.). Such assays may be direct, indirect, competitive, or noncompetitive as described in the art (see, e.g., *Principles and Practice of Immunoassay*, 1991, Eds. Christopher P. Price and David J. Neoman, Stockton Pres, NY, NY; and Oellrich, M., 1984, *J. Clin. Chem. Clin. Biochem.*, 22:895-904). Proteins may be isolated from test specimens and biological samples by conventional methods, as described in *Current Protocols in Molecular Biology*, *supra*.

Exemplary antibody molecules for detecting β_2 AR 5'LC peptide variants are intact immunoglobulin molecules, substantially intact immunoglobulin molecules, or those portions of immunoglobulin molecules that contain the antigen binding site.

Polyclonal or monoclonal antibodies may be produced by methods conventionally

5 known in the art (e.g., Kohler and Milstein, 1975, *Nature*, 256:495-497; Campbell "Monoclonal Antibody Technology, the Production and Characterization of Rodent and Human Hybridomas", 1985, In: "Laboratory Techniques in Biochemistry and Molecular Biology," Eds. Burdon et al., Volume 13, Elsevier Science Publishers, Amsterdam). The antibodies or antigen binding fragments thereof may also be
10 produced by genetic engineering. The technology for expression of both heavy and light chain genes in *E. coli* is the subject of PCT patent applications, publication number WO 901443, WO 901443 and WO 9014424 and in Huse et al., 1989, *Science*, 246:1275-1281. The antibodies may also be humanized (e.g., Queen, C. et al. 1989 *Proc. Natl. Acad. Sci.* 86:10029).

15 The above described genotyping methods are useful in methods for determining the frequency of a β_2 AR genotype or haplotype in a population. The method comprises determining the genotype or the haplotype pair for the β_2 AR 5' gene that is present in each member of the population and calculating the frequency any particular β_2 AR genotype or haplotype is found in the population. In a preferred
20 embodiment, the β_2 AR genotype may also comprise the nucleotide pair(s) detected at one or more additional β_2 AR polymorphic sites. The population may be a reference population, a family population, a same sex population, a population group, a trait population (e.g., a group of individuals exhibiting a trait of interest such as a medical condition or response to a therapeutic treatment).

25 Frequency data for such β_2 AR genotypes or haplotypes in reference and trait populations are useful for identifying an association between a trait and a β_2 AR 5'LC polymorphism, a β_2 AR genotype or a β_2 AR haplotype. The trait may be any detectable phenotype, including but not limited to genetic predisposition to a disease or response to a treatment. The method comprises obtaining data on the frequency of
30 the β_2 AR 5'LC polymorphism, β_2 AR genotype or β_2 AR haplotype of interest in a reference population as well as in a population exhibiting the trait. Frequency data for one or both of the reference and trait populations may be obtained by genotyping or

haplotyping each individual in the populations using one of the methods described above. In another embodiment, the frequency data for the reference and/or trait populations is obtained by accessing previously determined frequency data, which may be in written or electronic form. For example, the frequency data may be present in a database that is accessible by a computer. Once the frequency data is obtained, the frequencies of the 5'LC polymorphism, β_2 AR genotype or β_2 AR haplotype of interest are compared in the reference and trait populations. If a 5'LC polymorphism, β_2 AR genotype or β_2 AR haplotype is more frequent in the trait population than in the reference population to a statistically significant degree, then the trait is predicted to be associated with that 5'LC polymorphism, β_2 AR genotype or β_2 AR haplotype.

In a preferred embodiment of the method, the trait of interest is a clinical response exhibited by a patient to some therapeutic treatment, for example, response to a drug targeting β_2 AR or response to a therapeutic treatment for a medical condition. As used herein, "medical condition" includes but is not limited to any condition or disease manifested as one or more physical and/or psychological symptoms for which treatment is desirable, and includes previously and newly identified diseases and other disorders. As used herein the term "clinical response" means any or all of the following: a quantitative measure of the response, no response, and adverse response (i.e., side effects).

In order to deduce a correlation between a clinical response to a treatment and a 5'LC polymorphism, β_2 AR genotype or β_2 AR haplotype, it is necessary to obtain data on the clinical responses exhibited by a population of individuals who received the treatment, hereinafter the "clinical population". This clinical data may be obtained by analyzing the results of a clinical trial that has already been run and/or the clinical data may be obtained by designing and carrying out one or more new clinical trials. As used herein, the term "clinical trial" means any research study designed to collect clinical data on responses to a particular treatment, and includes but is not limited to phase I, phase II and phase III clinical trials. Standard methods are used to define the patient population and to enroll subjects.

It is preferred that the individuals included in the clinical population have been assessed for the clinical characteristics of the medical condition of interest. Such clinical characteristics may include symptoms, disease severity, response to therapy

and the like. This characterization is important in cases where the symptom(s) being presented by the patients can be caused by more than one underlying condition, and where treatment of the underlying conditions are not the same. An example of this would be where patients experience breathing difficulties that are due to either asthma
5 or respiratory infections. If both sets were treated with an asthma medication, there would be a spurious group of apparent non-responders that did not actually have asthma. These people would affect the ability to detect any correlation between haplotype and treatment outcome. Characterization of potential patients could employ a standard physical exam or one or more lab tests.

10 The therapeutic treatment of interest is administered to each individual in the trial population and each individual's response to the treatment is measured using one or more predetermined criteria. It is contemplated that in many cases, the trial population will exhibit a range of responses and that the investigator will choose the number of responder groups (e.g., none, low, medium, high) made up by the various
15 responses. In addition, the β_2 AR gene for each individual in the trial population is genotyped at least at the 5'LC polymorphic site, which may be done before or after administering the treatment.

After both the clinical and polymorphism data have been obtained,
20 correlations are created between individual response and the presence of a β_2 AR 5'LC polymorphism, β_2 AR genotype or β_2 AR haplotype. Correlations may be produced in several ways. In one embodiment, individuals are grouped by their β_2 AR genotype or β_2 AR haplotype and then the averages and standard deviations of clinical responses exhibited by the members of each group are calculated. These results are then
25 analyzed to determine if any observed variation in clinical response between genotype or haplotype groups is statistically significant. Another method involves categorizing the response (e.g., none, low, medium, high or other such grades) and then assessing whether a particular genotype is more common in one group of responders compared to another. Statistical analysis methods which may be used are described in L.D. Fisher and G. vanBelle, "Biostatistics: A Methodology for the Health Sciences",
30 Wiley-Interscience (New York) 1993.

It is also contemplated that the above methods for identifying associations between a β_2 AR 5'LC polymorphism, or β_2 AR genotypes and haplotypes containing

the β_2 AR polymorphism, may be performed in combination with genotype(s) and haplotype(s) for one or more additional genomic regions.

The above described genotyping and haplotyping methods are also useful for predicting an individual's predisposition to various diseases modified by the β_2 AR.

5 At the time the present invention was made, it was well-known in the medical arts that the β_2 AR is expressed in a number of tissues in the human body and that the amount of such expression modifies a number of diseases and physiologic processes. As an example, when activated by an agonist (or to a lesser extent by the endogenous agonist epinephrine), the β_2 AR relax airway smooth muscle and open the constricted

10 airways during an asthma attack. It follows, then, that a polymorphism that causes, for example, the β_2 AR to be minimally expressed in the lung would result in worse asthma (i.e., endogenous epinephrine doesn't work as well). The same logic is applied to β_2 AR expressed in other organs/cells in the body, with the predictable consequences of a low or high expression level due to a polymorphism. Thus, an

15 altered level of expression would be a risk factor for a disease or cause a more severe form of the indicated diseases in the right-hand column of Table 1.

Table 1. Location and Function of β_2 -adrenergic receptors in humans*

Location	Function	Disease Modifying
Heart	Increase rate Increase contractility	Congestive Heart Failure Arrhythmia Ischemic Heart Disease
Arterioles	Dilatation	Hypertension Migraine
Veins	Dilatation	Hypertension
Lungs (tracheal & bronchial smooth muscle)	Relaxation	Asthma COPD Anaphylaxis
Fat cells	Lipolysis	Obesity
Pancreas (islets)	Insulin secretion	Diabetes
Skeletal muscle	Glycogen breakdown	Diabetes
Uterus	Relaxation	Premature labor

*Adapted from Goodman and Gilman's *The Pharmacological Basis of Therapeutics*,
20 Pergamon Press, 1990, New York, pp 89-90.

A brief explanation of the expected effects of the β_2 AR 5' LC polymorphisms for each disease in Table 1 follows.

5 *Congestive heart failure* - In this syndrome the heart has decreased cardiac output which can be increased by activating β_2 AR which increase heart rate and the force of contraction. Thus, individuals homozygous for the C polymorphism at the β_2 AR 5' LC PS would have an increased risk for decompensation.

10 *Ischemic Heart Disease* - Individuals suffering from this condition have blocked coronary arteries and thus a limited capacity to tolerate increased cardiac demand. Thus, an increased cardiac output caused by increased levels of β_2 AR can lead to myocardial infarction in these patients. The skilled artisan would expect, therefore, that individuals suffering from ischemic heart disease who are homozygous for the β_2 AR 5'LC T polymorphism, which leads to higher levels of β_2 AR expression than the C allele, are at an increased risk of having a myocardial infarction.

15 *Cardiac arrhythmias* – Activated β_2 AR cause an increase in heart rate which predisposes certain individuals with conduction system defects to arrhythmias. Thus, the higher β_2 AR expression expected in individuals homozygous for T at the 5'LC polymorphic site would be a risk factor for arrhythmias.

20 *Hypertension* – Blood pressure is regulated, in part, by systemic vascular resistance which is due to contraction of the smooth muscle surrounding the small resistance arteries known as arterioles. β_2 AR are expressed on this muscle and thus activation relaxes it and lowers resistance and blood pressure. Because polymorphisms leading to lower expression would predispose to hypertension, an individual homozygous for C at the 5'LC PS would have an increased risk for developing hypertension.

25 *Vascular disease* – Diseases where vascular flow is compromised to a given organ, due to atherosclerosis or abnormal neurogenic control of tone, such as migraine, are amenable to treatment with vasodilators or vasoconstrictors. As discussed above, arterioles alter resistance and flow and are relaxed (opened) by β_2 AR. Thus, patients homozygous for the C polymorphism in the β_2 AR 5'LC, which causes decreased β_2 AR expression, would be at increased risk for a more severe form of obstructive or neurogenic vascular disease. Individuals homozygous for the T

polymorphism would be expected to be at increased risk of migraine headaches since they are genetically predisposed to cerebral vasodilation.

5 *Asthma, COPD, anaphylaxis*— The airways have smooth muscle which when contracted leads to obstruction of airflow, termed bronchospasm, in asthma, COPD (a syndrome with varying features of emphysema and chronic bronchitis), and anaphylaxis. β_2 AR on airway smooth muscle relax the muscle and open the airways. Therefore, patients homozygous for the C polymorphism in the β_2 AR 5'LC would be predisposed to bronchospasm.

Obesity – Fat cells express three β AR subtypes, including the β_2 AR.

10 Activation of the β_2 AR causes breakdown of fat in the cells. Thus, at the time the invention was made, the skilled artisan would have expected that a polymorphism causing reduced β_2 AR expression would be a risk factor for developing obesity since a lower efficiency of lipolysis in fat cells would be expected in individuals carrying this polymorphism. This expectation was recently confirmed by a clinical study, 15 which demonstrated that the 5' LC C polymorphism is indeed associated with obesity (29).

20 *Diabetes* – In diabetes, a decrease in insulin (or a resistance to insulin's action) causes elevated glucose levels in the blood. The islet cells of the pancreas are responsible for insulin secretion, and these cells express β_2 AR, which act to increase insulin secretions. At the time the invention was made, the skilled artisan would have expected that a polymorphism that causes decreased β_2 AR expression would result in lower insulin secretion and predispose to diabetes. Skeletal muscle glycogen metabolism is also altered by β_2 AR activation, and a complex interplay with insulin secretion and lipolysis (see above) can further the potential for the diabetic state. Of 25 note, this prediction is supported by the results of a recent clinical study, which found significant association between the 5' LC C polymorphism and Type 2 diabetes (29).

30 *Premature labor* – The uterine muscle expresses β_2 AR which serve to relax the muscle. β_2 AR agonists such as ritodrine are administered to inhibit contractions of the uterus when premature labor develops. Patients with a polymorphism that results in decreased β_2 AR expression would be predisposed to higher uterine muscle tone and at higher risk for early labor.

An individual's predisposition to these diseases can be predicted by determining the individual's genotype for the β_2 AR 5'LC polymorphic site. Although nucleic acid isolated from any tissue from the individual may be used for genotyping, the typical genotyping procedure comprises drawing a patient's blood and extracting 5 genomic DNA from the cells of the blood (e.g., peripheral blood mononuclear cells, leukocytes, or lymphocytes). In addition, if necessary and prudent, prenatal diagnosis can be accomplished by testing fetal cells or amniotic fluid. The identity of the nucleotide or nucleotide pair at the β_2 AR 5'LC polymorphic site can be determined by any of the means described herein.

10 As described in the Examples below, the inventor herein has discovered that asthmatic patients who are homozygous T at the 5'LC polymorphic site are less likely to exhibit a bronchodilating response to the β -agonist albuterol than asthmatic patients having other 5'LC genotypes. Thus, the invention also provides a method for predicting a patient's bronchodilating response to a β_2 -agonist, which comprises

15 determining the patient's genotype for the 5'LC PS. A patient who is homozygous T at this site is unlikely to exhibit a bronchodilating response to the β_2 -agonist while a patient who is homozygous C or heterozygous C/T at this site is likely to exhibit a bronchodilating response to the β_2 -agonist. As used herein, the term "bronchodilating response" means an increase of greater than 12% in the forced expiratory flow

20 between 25% and 75% of the forced vital capacity (FEF₂₅₋₇₅) after administration of the standard dose of the β_2 -agonist. Based on the patient's genotype for the 5'LC PS, the physician can determine whether the patient should be treated with higher doses of the β_2 -agonist, or with an alternative therapy. In a preferred embodiment of this method, the β_2 -agonist is albuterol.

25

Examples

The Examples herein are meant to exemplify the various aspects of carrying out the invention and are not intended to limit the scope of the invention in any way. The Examples do not include detailed descriptions for conventional methods employed, such as in the synthesis of oligonucleotides or preparation of antibodies. Such methods are well known to those skilled in the art and are described in numerous publication's, for example, Sambrook, Fritsch, and Maniatis, Molecular

Cloning: a Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, USA, (1989).

Example 1

This example illustrates the detection of a polymorphic site in the 5' leader cistron of the β_2 AR gene.

The study was approved by the University of Cincinnati College of Medicine Institutional Review Board. Genomic DNA was derived by the cetyltrimethyl ammonium bromide method (15) from peripheral blood obtained from 176 healthy Caucasian subjects without histories of chronic disease.

The first nucleotide of the initiator methionine codon of the β_2 AR coding block is denoted as nucleotide 1 and the adjacent 5' residue as nucleotide -1. The 5' leader cistron is thus localized to nucleotides -102 to -42 (nucleotides 1487-1546 of Fig. 1). A polymerase chain reaction was carried out using primers that provided for an amplification product spanning this region (sense: 5'-

AAGGACACCACCTCCAGCTTAG -3', (SEQ ID NO:11); antisense: 5'- CGCATGGCTTCTATTGGGTG -3' (SEQ ID NO:12). Each reaction contained 1 U of AmpliTaq polymerase (Perkin Elmer), 500 ng genomic DNA 250 μ M of each dNTP, and 37.5 pmol of each primer in a final volume of 50 μ l. After an initial denaturation step of 98 °C for 2 minutes, 35 cycles of 98 °C for 30 sec, 56 °C for 30 sec, and 72 °C for 30 sec were carried out, followed by a 7-minute final extension at 72 °C. Ten μ l of the PCR reaction was electrophoresed on a 1% agarose gel and visualized by ethidium bromide staining. The remaining PCR product was purified with a commercial kit (Promega) and was sequenced by an automated sequencer (ABI 377 Prism) using dye-terminator chemistry (Figure 4A). After sequencing 46 individuals, a single polymorphism of C or T at position -47, which corresponds to nucleotide 55 of the leader cistron ORF (nucleotide 1541 of Fig. 1), was identified. This polymorphic site in the 5'LC results in the encoded residue at amino acid 19 being either Arg or Cys.

A rapid detection method was subsequently developed based on the loss of an MspI restriction endonuclease site when T is present (Figure 4B). In this method, a target region defined by forward primer 5'- GCTGAATGAGGCTTCCAGGC -3'

(SEQ ID NO:13) and reverse primer 5'- CGCATGGCTTCTATTGGGTG -3' (SEQ ID NO:14).

As shown in Table 2 below, 13% of the 176 normal, unrelated subjects in this study were homozygous for the C (Arg19) allele and 39% were homozygous for the T (Cys19) allele, with the remainder being heterozygotes.

Table 2. Distribution of polymorphisms at position 19 of the 5'LC peptide.

Genotype	No.	%
Homozygous Arg	23	13
Heterozygous	85	48
Homozygous Cys	68	39

Thus, the allele frequencies were 0.37 for Arg and 0.63 for Cys in this population.

10 The number of homozygous and heterozygous alleles that were found is in agreement with that predicted by the Hardy-Weinberg relationship ($p=0.98$).

Example 2

This example illustrates the effect of the β_2 AR 5'LC polymorphisms on β_2 AR expression.

15 To test whether variation in the 5'LC altered receptor expression, cells were transiently transfected with two receptor constructs. These consisted of a contiguous stretch of 1989 bp exactly as found in the human gene, comprising a 93 bp region upstream of the leader cistron, the leader cistron with its stop codon, an additional intervening 41 bp of 5' sequence, the β_2 AR coding sequence and 557 bp of 3' untranslated region. This cDNA was subcloned into the expression vector pBC12BI at the BamHI site. The two constructs, denoted 5'LC-Arg19 and 5'LC-Cys19, differed only by the nucleotide at position -47. Of note, both constructs encoded for Gly at position 16 and Glu at position 27 in the β_2 AR coding block, which is the most common β_2 AR genotype. COS-7 cells were transfected by a DEA-Dextran method 20 with 15 μ g of either construct as previously described (17). Cells were maintained in Dulbecco's Modified Eagles medium in 10% fetal calf serum at 37 °C in a 95% air, 5% CO₂ atmosphere.

25 Two days after transfection, the confluent cells were harvested for determination of receptor expression by radioligand binding with [¹²⁵I]cyanopindolol ([¹²⁵I]CYP) using 1 μ M propranolol to define non-specific binding. Cells were

disrupted by scraping with a rubber policeman in cold 5 mM Tris, 2 mM EDTA, pH 7.4 buffer and the particulates centrifuged at 40,000 xg for 10 minutes and resuspended in 75 mM Tris, 12 mM MgCl₂, 2 mM EDTA, pH 7.4 buffer. Membranes (~10 µg) were incubated in triplicate with a saturating concentration of [¹²⁵I]CYP (400 pM) without or with propranolol in the aforementioned buffer for 2 hrs at 25 °C. The reaction was stopped by dilution and rapid vacuum filtration over Watman GF/C filters. Radioactivity was measured in a gamma counter at 80% efficiency. Protein was quantitated by the copper bicinchoninic method (19).

As shown in Figure 5A, the 5'LC-Cys19 construct resulted in 72% higher
10 levels of expression over that obtained with the 5'LC-Arg19 construct (4666 ±302 vs 2711 ±294 fmol/mg, P<0.01). This is consistent with the aforementioned studies (14), which showed that the Arg 5'LC peptide inhibited β₂AR translation.

To control for any possible differences in transfection efficiency in the two plates, additional studies were carried out using cells co-transfected with the above
15 constructs and a luciferase expression vector driven by the human β-actin promoter to provide for transient expression of firefly luciferase. Cells from one half of a 150 mm culture dish were scraped and used for membrane preparations as described above. Lysates prepared from the remaining cells were then assayed for luciferase expression using a commercial luciferase assay system (Promega). Luminescence was measured
20 using a Monolight 2010 luminometer (Analytical Luminescence Laboratory) and expressed per mg of protein in the lysate. To account for differences in transfection efficiency, the value for [¹²⁵I]CYP binding (fmol/mg protein) was divided by the value for luciferase expression (light units/mg protein). The corrected value is thus reported as fmol/light unit (fmol/LU). Again, as shown in Figure 5B, the 5'LC-Cys19
25 construct provided for higher β₂AR expression (130% increase) as compared to the Arg construct (656 ±90 vs 288 ±45 fmol/LU, n=4, P<0.01). Finally, adenylyl cyclase activities were determined in membranes from cells transfected with the two constructs. Consistent with the enhanced expression, isoproterenol stimulated activities were higher in membranes obtained from transfection with the 5'LC-Cys19
30 construct as compared to the 5'LC-Arg19 construct (66.2 ±4.5 vs 49.7 ±4.9 pmol/min/mg, P<0.02, n=5 experiments).

Assuming that the degree of DNA transfection was indeed the same between the two constructs, and the difference in β_2 AR cellular expression was due to differences in peptide mediated inhibition of translation (rather than transcription or mRNA stability), then there should be no differences in β_2 AR mRNA levels between 5 cells transfected with one construct versus the other. To assess this, mRNA levels were determined by a quantitative ribonuclease protection assay which included a probe for β -actin as a control.

Total cellular RNA was prepared from transfected cells by an acid guanidinium thiocyanate-phenol-chloroform extraction reagent (Molecular Research, 10 Cincinnati, OH) and β_2 AR transcripts delineated by ribonuclease protection assays (RPA) in a manner similar to that previously described (18). A template for the synthesis of riboprobes was prepared by subcloning a cDNA encoding the β_2 AR ORF into the HindIII/XbaI sites of plasmid pSP72 (Promega). Plasmid linearized with EcoNI was then used for *in vitro* transcription reactions with T7 polymerase and 15 [32 P]UTP to generate a 563 bp antisense riboprobe corresponding to the distal 500 bp of the β_2 AR ORF. In addition, a radiolabeled antisense riboprobe for β -actin was generated from a commercial template (Ambion) using T7 polymerase. RPAs were performed as previously reported (18) by hybridizing 20 μ g of total cellular RNA 20 with both the actin and β_2 AR riboprobes. The hybridized products were digested with RNase A and T1, after which protected fragments were separated by electrophoresis on 6% polyacrylamide gels containing 8M urea. Radiographic bands corresponding to the protected fragments were visualized with a PhosphoImager (Molecular Dynamics) and conventional autoradiography. Band density was quantitated on the phosphorimage with the ImageQuant software package (Molecular Dynamics). To 25 account for minor differences in sample loading and recovery, the measured value for the β_2 AR protected fragment was normalized to that of β -actin in the same sample. The results of these ribonuclease protection assays are shown in Figure 6. In four independent experiments, β_2 AR mRNA levels were found to be indistinguishable between cells transfected with the two constructs (as were transcripts for β -actin).

Having shown that the 5' cistron polymorphisms had differential effects on β_2 AR expression in a recombinant system, we wondered whether receptor expression correlated with the 5' leader cistron polymorphism in cells that endogenously express

the β_2 AR. Human airway smooth muscle was chosen because it expresses exclusively β_2 AR, and the receptors on this cell have known physiologic relevance. Human airway smooth muscle cells were obtained by rapid autopsy from individuals without lung disease. These cells were established and maintained in primary culture 5 as previously described (5), genotyped and radioligand binding carried out as described above.

Of note, linkage disequilibrium exists between the 5' LC and the coding block polymorphisms (see below), and a limited number of human airway smooth muscle cell lines available were homozygous for the 5' LC polymorphisms. Thus, matches at 10 positions 16 and 27 between the two cell lines were not utilized. (The 5' LC-Arg cells were homozygous for Gly and Glu at coding positions 16 and 27, while the 5' LC-Cys cells were Arg and Gln.) Nevertheless, a clear difference in β_2 AR expression was found. As shown in Figure 7, for cells homozygous for the 5'LC-Arg19 polymorphism, [125 I]CYP binding revealed β_2 AR expression of 44 ± 10 fmol/mg. As 15 was seen with the recombinant studies, those with the 5'LC-Cys polymorphism had higher expression levels, which amounted to 84 ± 12 fmol/mg (n=5, P<0.02).

Example 3

This example illustrates there is linkage disequilibrium between the previously 20 described polymorphisms at nucleotides 46 and 79 (amino acids 16 and 27 of the receptor protein) and the 5' leader cistron polymorphisms.

To assess linkage disequilibrium between these polymorphic sites, some of the normal subjects underwent genotyping at all 3 sites. The polymorphisms at 25 nucleotides 46 and 79 in the β_2 AR coding block were detected by the genetic bit analysis technique (16). For this analysis, only those subjects that were homozygous were utilized so as to unequivocally assign haplotypes. These results (shown in Table 3) show linkage disequilibrium between the Cys 5' leader cistron polymorphism and the Gln27 coding block polymorphism (P<0.0001) and to a lesser extent the Arg16 coding block polymorphism. The frequencies of other genotypic combinations at 30 these three positions are shown in Table 4.

Table 3. Haplotypes of β_2 AR polymorphisms in the 5' cistron and the coding block*.

	<u>5' leader cistron</u>		
	<u>Arg19</u>	<u>Cys19</u>	<u>Pvalue</u>
Coding block	Arg16	0	19
	Gly16	19	6
	Gln27	0	42
	Glu27	18	0

* Shown are the number of subjects in each group.

Table 4. Genotypes at three polymorphic loci of the β_2 AR gene (n=130

5

subjects).*

	<u>Genotype</u>			<u>No.</u>	<u>% Total</u>
	<u>5'LC19</u>	<u>cb16</u>	<u>cb27</u>		
het	het	het	het	41	31.5
het	Gly	het	het	25	19.2
Cys	Arg	Gln	19	14.6	
Arg	Gly	Glu	18	13.8	
Cys	het	Gln	17	13.1	
Cys	Gly	Gln	6	4.6	
het	het	Gln	1	0.8	
Arg	Gly	het	1	0.8	
Cys	het	het	1	0.8	
het	Gly	Gln	1	0.8	

* 5'LC19, β_2 AR 5' leader cistron; cb, β_2 AR coding block; het, heterozygous; Arg, Cys, Gln, Glu represent homozygous alleles at these positions.

10

Example 4

This example illustrates there is an association between TT genotype at the β_2 AR 5'LC polymorphic site and lack of response to albuterol.

For this study, 134 patients with asthma were enrolled to determine whether either of the polymorphisms at nucleic acid -47 in the β_2 AR gene alter the

bronchodilating response to β -agonist. The percent (%) change in the forced expiratory flow between 25% and 75% of the forced vital capacity (FEF_{25-75}) was used as a measure of responsiveness. Patients underwent pulmonary function testing to measure FEF_{25-75} and then received 2 puffs (total of 180 micrograms) of aerosolized albuterol by metered dose inhaler. Thirty minutes later the FEF_{25-75} measurement was repeated. Based on accepted national standards, an increase in FEF_{25-75} of greater than 12% was considered a response, while 12% or less was considered no response.

As shown in Figure 8, there was a clear difference in the number of responders depending on genotype. Only 28.8% of patients with the TT genotype at the 5'LC PS exhibited a bronchodilating response to albuterol, while 71.1% of those without this genotype (TC or CC) had a response. The p value for this comparison by Chi-square analysis was $p=0.03$, which is statistically significant based on customary standards that p values less than 0.05 represent statistical significance. In addition, the odds ratio for having no response to albuterol if a patient had the TT genotype is 2.47. These results were not confounded by the severity of the asthma or whether the patient had allergic or non-allergic asthma. Thus, it is believed the TT genotype for the 5'LC PS is a specific marker for lack of responsiveness to albuterol. Conversely, the CC genotype and C/T genotype are markers for responsiveness to albuterol.

In view of the above, it will be seen that the several advantages of the invention are achieved and other advantageous results attained.

As various changes could be made in the above methods and compositions without departing from the scope of the invention, it is intended that all matter contained in the above description and shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.

All references cited in this specification, including patents and patent applications, are hereby incorporated in their entirety by reference. The discussion of references herein is intended merely to summarize the assertions made by their authors and no admission is made that any reference constitutes prior art. Applicants reserve the right to challenge the accuracy and pertinency of the cited references.

References

1. Reihsaus, E., M. Innis, N. MacIntyre, and S.B. Liggett. 1993. Mutations in the gene encoding for the β_2 -adrenergic receptor in normal and asthmatic subjects. *Am J Resp Cell Mol Biol* 8:334-339.
- 5 2. Liggett, S.B. 1995. Functional properties of human β_2 -adrenergic receptor polymorphisms. *News in Physiologic Sciences* 10:265-273.
3. Green, S., J. Turki, M. Innis, and S.B. Liggett. 1994. Amino-terminal polymorphisms of the human β_2 -adrenergic receptor impart distinct agonist-promoted regulatory properties. *Biochem* 33:9414-9419.
- 10 4. Green, S.A., G. Cole, M. Jacinto, M. Innis, and S.B. Liggett. 1993. A polymorphism of the human β_2 -adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. *J Biol Chem* 268:23116-23121.
5. Green, S.A., J. Turki, P. Bejarano, I.P. Hall, and S.B. Liggett. 1995.
- 15 6. Liggett, S.B. 1996. The genetics of β_2 -adrenergic receptor polymorphisms: relevance to receptor function and asthmatic phenotypes. In *The Genetics of Asthma*. S.B. Liggett and D.A. Meyers, editors. Marcel Dekker, New York. 455-478.
7. Turki, J., J. Pak, S. Green, R. Martin, and S.B. Liggett. 1995. Genetic polymorphisms of the β_2 -adrenergic receptor in nocturnal and non-nocturnal asthma: evidence that Gly16 correlates with the nocturnal phenotype. *J Clin Invest* 95:1635-1641.
- 20 8. Hall, I.P., A. Wheatley, P. Wilding, and S.B. Liggett. 1995. Association of the Glu27 β_2 -adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. *Lancet* 345:1213-1214.
9. Martinez, F.D., P.E. Graves, M. Baldini, S. Solomon, and R. Erickson. 1997. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. *J Clin Invest* 100:3184-3188.
- 30 10. Dewar, J.C., J. Wilkinson, A. Wheatley, N.S. Thomas, I. Doull, N. Morton, P. Lio, J. Harvey, S.B. Liggett, I.S. Holgate, and I.P. Hall. 1997. The

glutamine 27 β_2 -adrenoceptor polymorphism is associated with elevated immunoglobulin E levels in asthmatic families. *J Allergy Clin Immunol* 100:261-265.

11. Tan, S., I.P. Hall, J. Dewar, E. Dow, and B. Lipworth. 1997. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator

5 desensitization in moderately severe stable asthmatics. *Lancet* 350:995-999.

12. Kobilka, B.K., R.A.F. Dixon, T. Frielle, H.G. Dohlman, M.A. Bolanowski, I.S. Sigal, T.L. Yang-Feng, U. Franke, M.G. Caron, and R.J. Lefkowitz. 1987. cDNA for the human β_2 -adrenergic receptor: a protein with multiple membrane spanning domains and a chromosomal location shared with PDGF receptor gene.

10 *Proc.Natl.Acad.Sci., USA* 84:46-50.

13. Kobilka, B.K., T. Frielle, H.G. Dohlman, M.A. Bolanowski, R.A.F. Dixon, P. Keller, M.G. Caron, and R.J. Lefkowitz. 1996. Delineation of the intronless nature of the genes for the human and hamster β_2 -adrenergic receptor and their promoter agonists; *J.Biol.Chem.*: 262:7321-7327.

15 14. Parola, A.L. and B.K. Kobilka. 1994. The peptide product of a 5' leader cistron in the beta 2 adrenergic receptor mRNA inhibits receptor synthesis. *J Biol Chem* 269:4497-4505.

15. Jones, A.S. 1963. Use of Alkytrimethylammonium Bromide for the Isolation of Ribo- and Deoxyribo-nucleic Acid. *Nature* 199:280-282.

20 16. Nikiforov, T.T., R.B. Rendle, P. Goelet, Y.-H. Rogers, M.L. Kotewicz, S. Anderson, G.L. Trainor, and M.R. Knapp. 1994. Genetic Bit Analysis: a solid phase method for typing single nucleotide polymorphisms. *Nucleic Acids Research* 22:4167-417S.

25 17. McGraw, D.W., E.T. Donnelly, M.G. Eason, S.A. Green, and S.B. Liggett. 1998. Role of β ARK in long-term agonist-promoted desensitization of the β_2 -adrenergic receptor. *Cell Signal* 10:197-204.

18. McGraw, D.W. and S.B. Liggett. 1997. Heterogeneity in β ARK expression in the lung accounts for cell-specific desensitization of the β_2 -adrenergic receptor. *J.Biol.Chem.* 272:7338-7343.

30 19. Smith, P.K., R.I. Krohn, G.T. Hermanson, A.K. Mallia, F.H. Gartner, M.D. Provenzano, E.K. Fujimoto, N.M. Goeke, B.J. Olson, and D.C. Klenk. 1988. Measurement of protein using bicinchoninic acid. *Anal.Biochem.* 150:76-85.

20. Calnan, B.J., B. Tidor, S. Biancalana, D. Hudson, and A.D. Frankel. 1991. Arginine-Mediated RNA Recognition: The Arginine Fork. *Science* 252:1167-1171.

21. Fedyk, E.R., A.A. Looney, and R.P. Phipps. 1996. Regulation of IgE and cytokine production by cAMP: implications for extrinsic asthma. *Clin Immunol Immunopathol* 81:101-113.

5 22. Themmen, A.P.N., J.W.M. Martens, and H.G. Brunner. 1997. Gonadotropin receptor mutations. *J Endocrinol* 153:179-183.

23. Chattopadhyay, N., A. Mithal, and E.M. Brown. 1996. The calcium-sensing receptor: a window into the physiology and pathophysiology of mineral ion

10 metabolism. *Endocr Rev* 17:289-307.

24. Rosenthal, W., A. Antaramian, S. Gilbert, and M. Bimbaumer. 1993. Nephrogenic diabetes insipidus: a V2 vasopressin receptor unable to stimulate adenylyl cyclase. *J Biol Chem.* 268:13030-13033.

25. Gether, U., J.A. Ballesteros, R. Seifert, E. Sanders-Bush, H. Weinstein, and B.K. Kobilka. 1997. Structural instability of a constitutively active G protein-coupled receptor. *J Biol Chem.* 272:2587-2590.

15 26. Kotanko, P., A. Binder, J. Tasker, P. DeFreitas, S. Kamdar, A.J. Clark, F. Skrabal, and M. Caulfield. 1997. Essential hypertension in African Caribbean's associates with a variant of the beta2-adrenoceptor. *Hypertension* 30:773-776.

20 27. Large, V., L. Hellstrom, S. Reynisdottir, F. Lonnqvist, P. Eriksson, L. Lannfelt, and P. Amer. 1997. Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. *J Clin Invest* 100:3005-3013.

28. Thomson, J.A. et al. 1998. Embryonic Stem cell lines derived from human

25 blastocysts. *Science* 282:1145-1147.

29. Yamada K, et al., 1999. Polymorphism in the 5'-leader cistron of the β_2 -adrenergic receptor gene associated with obesity and type 2 diabetes. *J. Clin. Endocrinol. & Metabol.* 84:1754-1757, 1999.

What is Claimed is:

1. A method for genotyping the β_2 -adrenergic receptor (β_2 AR) gene of an individual, which comprises determining the identity of the nucleotide pair at the 5' leader cistron (5'LC) polymorphic site (PS) in the two copies of the β_2 AR gene present in the individual.
2. The method of claim 1, wherein the determining step comprises
 - (a) isolating from the individual a nucleic acid mixture comprising both copies of the β_2 AR gene, or a fragment thereof, present in an individual;
 - (b) amplifying a target region containing the 5'LC PS; and
 - (c) detecting the presence of one or both of cytosine or thymine at the 5'LC PS.
3. The method of claim 2, wherein the detecting step comprises:
 - (a) incubating the amplified target region with MspAII; and
 - (b) analyzing the incubation mixture for the presence of MspAII digestion products.
4. The method of claim 2, wherein the detecting step comprises hybridizing the amplified target region with an allele-specific oligonucleotide (ASO) probe which specifically hybridizes to a β_2 AR 5'LC allele comprising the thymine polymorphism or to a β_2 AR 5'LC allele comprising the cytosine polymorphism.
5. The method of claim 4, wherein the ASO probe comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:5, the complement of SEQ ID NO:5, SEQ ID NO:6, and the complement of SEQ ID NO:6.
6. The method of claim 2, wherein the detecting step comprises sequencing the amplified target region.
7. The method of claim 2, wherein the amplifying step is performed by the polymerase chain reaction method using at least one allele-specific primer which specifically hybridizes to a β_2 AR 5'LC allele selected from the group consisting of a first β_2 AR 5'LC allele comprising the thymine polymorphism, the complement of the first β_2 AR 5'LC allele, a second

β_2 AR 5'LC allele comprising the cytosine polymorphism, and the complement of the second β_2 AR 5'LC allele.

8. The method of claim 7, wherein the allele-specific primer is selected from the group consisting of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10.
9. A method for detecting which 5' β_2 AR 5'LC peptide variant is expressed in an individual, which comprises contacting a biological sample from the individual with a first antibody that is specifically immunoreactive with a first 5'LC peptide variant and detecting a complex formed between the first antibody and the first 5'LC peptide variant.
5
10. The method of claim 9, further comprising contacting the biological sample with a second antibody that is specifically immunoreactive with the second 5'LC peptide variant and detecting a complex formed between the second antibody and the second 5'LC peptide variant.
11. The method of claim 1, which further comprises determining the identity of the nucleotide pair at one or more additional polymorphic sites in the β_2 AR gene.
12. The method of claim 10, wherein the additional polymorphic sites are selected from the group consisting of -20PS, +46PS, +79PS, +100PS and +491PS.
13. A composition comprising at least one allele-specific oligonucleotide (ASO) that specifically hybridizes to a β_2 AR polynucleotide at a region containing the 5'LC polymorphic site.
14. The composition of claim 13, wherein the ASO is a probe comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:5, the complement of SEQ ID NO:5, SEQ ID NO:6, and the complement of SEQ ID NO:6.
15. The composition of claim 13, wherein the ASO is a primer comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10.
16. A method for haplotyping the β_2 -adrenergic receptor (β_2 AR) gene in an individual, comprising

0 9 8 5 5 6 8 0 2 6 5 2 6 0 4

5 (a) isolating from the individual a nucleic acid molecule containing only one of the two copies of the β_2 AR gene, or a fragment thereof, that is present in the individual; and

(b) determining in that copy the identity of the nucleotide at the 5' LC PS and at one or more additional β_2 AR polymorphic sites.

17. The method of claim 16, wherein the additional polymorphic sites are selected from the group consisting of -20PS, +46PS, +79PS, +100PS and +491PS.

5 18. A method for predicting an individual's genotype for at least one coding block polymorphic site (cb PS) in the β_2 -adrenergic receptor gene, which comprises determining the individual's genotype for the 5' leader cistron polymorphic site (5'LC PS) and assigning a genotype for the cb PS which is consistent with the individual's 5'LC PS genotype, wherein the cb PS is selected from the group consisting of +46PS and +79PS.

19. A method for determining the frequency of a β_2 AR genotype or haplotype in a population, comprising

5 (a) determining the genotype or the haplotype pair for the β_2 AR 5' gene that is present in each member of the population and

(b) calculating the frequency any particular β_2 AR genotype or haplotype is found in the population.

5 20. The method of claim 19, wherein the population is a trait population and the trait is selected from the group consisting of congestive heart failure, ischemic heart disease arrhythmia, hypertension, migraine asthma, chronic obstructive pulmonary disease (COPD), anaphylaxis, obesity, diabetes and premature labor.

5 21. A method for identifying an association between a polymorphism in the β_2 AR 5' leader cistron and a trait, which comprises comparing the frequency of the polymorphism in a population exhibiting the trait with the frequency of the polymorphism in a reference population, wherein a higher frequency of the polymorphism in the trait population than in the reference population indicates the polymorphism is associated with the trait.

22. The method of claim 21, wherein the trait is susceptibility to a disease or condition selected from the group consisting of congestive heart failure, ischemic heart disease arrhythmia, hypertension, migraine, asthma, chronic obstructive pulmonary disease (COPD), anaphylaxis, obesity, diabetes and premature labor.

5 23. The method of claim 22, wherein the trait is response to an agonist or antagonist of β_2 AR.

24. A method for predicting a patient's predisposition to a disease or condition modified by the β_2 AR, which comprises determining the individual's genotype for the β_2 AR 5'LC polymorphic site.

25. The method of claim 24, wherein the disease or condition is selected from the group consisting of congestive heart failure, ischemic heart disease arrhythmia, hypertension, migraine, asthma, chronic obstructive pulmonary disease (COPD), anaphylaxis, obesity, diabetes and premature labor.

5 26. A method for predicting a patient's bronchodilating response to an agonist of β_2 AR, which comprises determining the patient's genotype for the β_2 AR 5'LC polymorphic site, wherein a patient who is homozygous T at this site is unlikely to exhibit a bronchodilating response to the agonist.

27. The method of claim 26, wherein the agonist is albuterol.

1/8

CCGGGGTTCA	AGAGATTCTC	CTGTCTCAGC	CTCCCGAGTA	GCTGGGACTA	
CAGGTACGTG	CCACCACACC	TGGCTAATT	TTGTATTTT	AGTAGAGACA	100
AGAGTTACAC	CATATTGGCC	AGGATCTTT	GCTTCATA	GCTTCAAAAT	
GTTCTTAATG	TTAAGACATT	CTTAATACTC	TGAACCATAT	GAATTGCCA	200
TTTTGGTAAG	TCACAGACGC	CAGATGGTGG	CAATTCA	TGGCACAAACC	
CGAAAGATTA	ACAAACTATC	CAGCAGATGA	AAGGATTTT	TTTAGTTCA	300
TTGGGTTTAC	TGAAGAAATT	GTTGAAATT	TCATTGCATC	TCCAGTTCAA	
CAGATAATGA	GTGAGTGATG	CCACACTCTC	AAGAGTTAAA	AACAAAACAA	400
CAAAAAAATT	AAAACAAAAG	CACACAAC	TCTCTCTG	TCCCAAAATA	
CATACTTGCA	TACCCCCGCT	CCAGATAAAA	TCCAAAGG	AAAACGTCT	500
TCATGCCTGC	AAATTCTAA	GGAGGGCACC	TAAAGTACTT	GACAGCGAGT	
GTGCTGAGGA	AATCGGCAGC	TGTTGAAGTC	ACCTCCTGTG	CTCTGCCAA	600
ATGTTTGAAA	GGGAATACAC	TGGGTTACCG	GGTGTATGTT	GGGAGGGGAG	
CATTATCAGT	GCTCGGGTGA	GGCAAGTTG	GAGTACCCAG	ATGGAGACAT	700
CCGTGTCTGT	GTCGCTCTGG	ATGCCTCAA	GCCAGCGTGT	TTTACTTTC	
TGTGTGTGTC	ACCATGTCTT	TGTGCTTCTG	GGTGCTTCTG	TGTTTGTTC	800
TGGCCGGCGT	TCTGTGTTGG	ACAGGGTGA	CTTGTGCCG	GATGGCTTCT	
GTGTGAGAGC	GCGCGCGAGT	GTGCATGTCG	GTGAGCTGGG	AGGGTGTGTC	900
TCAGTGTCTA	TGGCTGTGGT	TCGGTATAAG	TCTGAGCATG	TCTGCCAGGG	
TGTATTGTG	CCTGTATGTG	CGTGCCTCGG	TGGCACTCT	CGTTTCCTTC	1000
CGAATGTGGG	GCAGTGCCGG	TGTGCTGCC	TCTGCCTTGA	GACCTCAAGC	
CGCGCAGGCG	CCCAGGGCAG	GCAGGTAGCG	GCCACAGAAG	AGCCAAAAGC	1100
TCCCGGGTTG	GCTGGTAAGG	ACACCACCTC	CAGCTTTAGC	CCTCTGGGC	
CAGCCAGGGT	AGCCGGGAAG	CAGTGGTGGC	CCGCCCTCCA	GGGAGCAGTT	1200
GGGCCCGGCC	CGGGCCAGCC	CCAGGAGAAG	GAGGGCGAGG	GGAGGGGAGG	
GAAAGGGGAG	GAGTGCCTCG	CCCCTTCGCG	GCTGCCGGCG	TGCCATTGGC	1300
CGAAAGTTCC	CGTACGTAC	GGCGAGGGCA	GTTCCCCTAA	AGTCCGTGTC	
ACATAACGGG	CAGAACGAC	TGCGAAGCGG	CTTCTTCAGA	GCACGGGCTG	1400
GAAC TGCGAG	GCACCGCGAG	CCCCTAGCAC	CCGACAAGCT	GAGTGTGCA	
GACGAGTCCC	CACCAACACC	ACACCACAGC	CGCTGAATGA	GGCTCCAGG	1500
CGTCCGCTCG	CGGCCCGCAG	AGCCCCGCCG	TGGGTCCGCC	CGCTGAGGCG	
CCCCCAGCCA	GTGCGCTTAC	CTGCCAGACT	GCGGCCATG	GGGCAACCCG	1600
GGAACGGCAG	CGCCTTCTTG	CTGGCACCCA	ATAGAAGCCA	TGCGCCGGAC	
CACGACGTCA	CGCAGCAAAG	GGACGAGGTG	TGGGTGGTGG	GCATGGGCAT	1700
CGTCATGTCT	CTCATCGTCC	TGCCATCGT	GTTGGCAAT	GTGCTGGTCA	
TCACAGCCAT	TGCCAAGTTC	GAGCGTCTGC	AGACGGTCAC	CAACTACTTC	1800
ATCACTTCAC	TGGCCTGTG	TGATCTGGTC	ATGGGCCTGG	CAGTGGTGCC	
CTTTGGGGCC	GCCCATATT	TTATGAAAAT	GTGGACTTTT	GGCAACTTCT	1900
GGTGCAGGTT	TTGGACTTCC	ATTGATGTGC	TGTGCGTCAC	GGCCAGCATT	
GAGACCTGT	CGGTGATCGC	AGTGGATCGC	TACTTGC	TTACTTCACC	2000
TTTCAAGTAC	CAGAGCCTGC	TGACCAAGAA	TAAGGCCCGG	GTGATCATTC	
TGATGGTGTG	GATTGTGTCA	GGCCTTACCT	CCTTCTTGCC	CATTAGATG	2100
CACTGGTACC	GGGCCACCCA	CCAGGAAGCC	ATCAACTGCT	ATGCCAATGA	
GACCTGCTGT	GACTTCTCA	CGAACCAAGC	CTATGCCATT	GCCTCTTCCA	2200
TCGTGTCTT	CTACGTTCCC	CTGGTGTATCA	TGGTCTTCGT	CTACTCCAGG	
GTCTTCAGG	AGGCCAAAAG	GCAGCTCCAG	AAGATTGACA	AATCTGAGGG	2300
CCGCTTCCAT	GTCCAGAACCC	TTAGGCCAGGT	GGAGCAGGAT		

FIGURE 1

09/856 803

WO 00/31307

PCT/US99/27963

2/8

ATGAGGCTTC CAGGCGTCCG CTCGCGGCC GCAGAGCCCC GCCGTGGGTC CGCCTGCTGA

FIGURE 2

09/856803
PCT/US99/27963

WO 00/31307

3/8

MRLPGVRSRPAEPRRGGSAC

FIGURE 3

4/8




Figure 4A




Figure 4B

FIGURE 5B





FIGURE 5A



6/8




Figure 6

7/8





FIGURE 7

8/8

**FIGURE 8**

COMBINED DECLARATION AND POWER OF ATTORNEY

**(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, DIVISIONAL,
CONTINUATION, OR C-I-P)**

As a below named inventor, I hereby declare that:

TYPE OF DECLARATION

This declaration is for a national stage of PCT application.

INVENTORSHIP IDENTIFICATION

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am the original, first and sole inventor of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

Polymorphisms in the 5' Leader Cistron of the Beta2-Adrenergic Receptor

SPECIFICATION IDENTIFICATION

The specification is attached hereto.

AMENDMENT IDENTIFICATION

The PCT Article 19 amendment filed with the International Bureau on May 1, 2000 and the two preliminary amendments, which are attached.

ACKNOWLEDGMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, Section 1.56, and which is material to the examination of this application, namely, information where there is a substantial likelihood that a reasonable Examiner would consider it important in deciding whether to allow the application to issue as a patent, and in compliance with this duty, there is attached an information disclosure statement, in accordance with 37 C.F.R. Section 1.98.

POWER OF ATTORNEY

I hereby appoint the following practitioner(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

APPOINTED PRACTITIONER(S)

Melodie W. Henderson	34,848
Inna Shtivelband	44,337
Gisela M. Field	47,562
Sandra L. Shaner	47,934

REGISTRATION NUMBER(S)

SEND CORRESPONDENCE TO
Gisela M. Field
5 Science Park
New Haven, CT 06511

Customer Number 25106

DIRECT TELEPHONE CALLS TO:
Gisela M. Field
(203) 786-3473

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SIGNATURE

100 Stephen B. Liggett
Inventor's signature

Date 5-18-01

Residence 8020 Elbrecht Drive, Cincinnati, OH 45242

Country of Citizenship USA

45242

OH

Please type a plus sign (+) inside this box →

PTO/SB/82 (11-96)

Approved for use through 6/30/99. OMB 0651-0035

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REVOCATION OF POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

Application Number	
Filing Date	05/25/2001
First Named Inventor	Stephen B. Liggett
Group Art Unit	
Examiner Name	
Attorney Docket Number	MWH-0029US

I hereby revoke all previous powers of attorney or authorizations of agent given in the above-identified application:

A Power of Attorney or Authorization of Agent is submitted herewith.

OR

Please change the correspondence address for the above-identified application to:

Customer Number →

Place Customer
Number Bar Code
Label here

OR

<input type="checkbox"/> Firm or Individual Name			
Address			
Address			
City			
Country	State	ZIP	
Telephone	Fax		

I am the:

Applicant.

Assignee of record of the entire interest
Certificate under 37 CFR 3.73(b) is enclosed

SIGNATURE of Applicant or Assignee of Record

Name	Stephen B. Liggett
Signature	
Date	5/18/01

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

WO 00/31307

- 1 -

SEQUENCE LISTING

<110> LIGGETT, Stephen B.
UNIVERSITY OF CINCINNATI

<120> POLYMORPHISMS IN THE 5' LEADER CISTRON OF THE
BETA2-ADRENERGIC RECEPTOR

<130> 16570-2265b

<140>
<141>

<150> 60/109, 886

<151> 1998-11-25

<160> 14

<170> PatentIn Ver. 2.0

<210> 1
<211> 2340
<212> DNA
<213> Homo

<400> 1
ccgggttca agagattctc ctgtctcagc ctcccgagta gctgggacta caggtacgtg 60
ccaccacacc tggtaattt ttgtatTTT agtagagaca agagtacac catattggcc 120
aggatcttt gcttctata gcttcaaaat gttcttaatg ttaagacatt ctaataatcc 180
tgaaccatAT gaatttgcA ttttggtaag tcacagacgc cagatggtg caatttcaca 240
tggcacaacc cgaagatta acaaactata cagcagatga aaggatTTT tttagttca 300
ttgggttacA tgaagaattt gttgaattc tcattgcAtc tccagttca cagataatga 360
gtgagtgtatc ccacactctc aagagttAA aacaaacAA caaaaaattt aaaacaaaAG 420
cacacaactt tctctctctg tcccAAaaata catacttgca tacccccgct ccagataaaa 480
tccaaagggt aaaactgtct gacagcgagt gtgctgagga atgtttgaaa gggaaatacac gctcggtga ggcaagttcg atgcctccaa gccagcgtgt ggtgtctcg tgggttaccc gatggcttc tggtagagc tcagtgtcta tggctgtgtt cctgtatgtg cgtgcctcg tggcacttgc tggcgtccc tctgccttga gcccacagaag accaaaaAG cctctggggc cagccagggt gggcccccgc cgggccagcc gagtgcctcg ccccttcgcg ggcgagggcA gttccctcaa ctcttcgtca gcacgggctg gagtgtgcg gacgatgtccc cgtccctcg cggcccgagcA gtcgccttac ctgcccagact ctggcaccca atagaagcca tgggtgtgg gcatgggcat gtgctgtca tcacagccat atcacttcac tggcctgtc gcccatttc ttatgaaaat gtggactttt attgtgtgc tggcgtca cttttgttgcA ttacttcacA tttcaagttc gtagtggtgc cactgttaccA gggccaccca ccaGgaAGCC atcaactgtc gactttctca cgaaccaAGC ctagccatt gccttccca tgggtgtatca tggtcttcgt ctactccagg gtcttcagg aagattgaca aatctgaggg cccgtttccat gtccagaacc tttagccaggt ggagcaggat 2340

-2-

<210> 2
<211> 60

<212> DNA
<213> Homo sapiens

<400> 2

atgaggcttc caggcggtccg ctcgcggccc gcagagcccc gccgtgggtc cgccctgctga 60

<210> 3

<211> 19
<212> PRT
<213> Homo sapiens

<400> 3

Met Arg Leu Pro Gly Val Arg Ser Arg Pro Ala Glu Pro Arg Arg Gly
1 5 10 15

Ser Ala Cys

<210> 4

<211> 19
<212> PRT
<213> Homo sapiens

<400> 4

Met Arg Leu Pro Gly Val Arg Ser Arg Pro Ala Glu Pro Arg Arg Gly
1 5 10 15

Ser Ala Arg

<210> 5

<211> 15
<212> DNA
<213> Homo sapiens

<400> 5

gtccggccgc tgagg 15

<210> 6

<211> 15
<212> DNA
<213> Homo sapiens

<400> 6

gtccgcctgc tgagg 15

<210> 7

<211> 20
<212> DNA
<213> Homo sapiens

<400> 7

ccccggccgtg ggtccgcccc 20

<210> 8

<211> 20
<212> DNA
<213> Homo sapiens

<400> 8

ccccggccgtg ggtccgcctg 20

-3-

<210> 9
<211> 20
<212> DNA
<213> Homo sapiens

<400> 9
ggctggggc gcctcagcgg

20

<210> 10
<211> 20
<212> DNA
<213> Homo sapiens

<400> 10
ggctggggc gcctcagcag

20

<210> 11
<211> 23
<212> DNA
<213> Homo sapiens

<400> 11
aaggacacca cctccagctt tag

23

<210> 12
<211> 20
<212> DNA
<213> Homo sapiens

<400> 12
cgcatggctt ctattgggtg

20

<210> 13
<211> 20
<212> DNA
<213> Homo sapiens

<400> 13
gctgaatgag gcttccaggc

20

<210> 14
<211> 20
<212> DNA
<213> Homo sapiens

<400> 14
cgcatggctt ctattgggtg

20